NEXIUM® (esomeprazole magnesium) demonstrated better efficacy than lansoprazole (Prevacid®) in preventing a recurrence in patients with healed erosive esophagitis (EE) and is equally effective in reducing its associated symptoms.
AstraZeneca (NYSE: AZN)‘s NEXIUM® is approved for treating frequent, persistent heartburn and other symptoms associated with acid reflux disease as well as healing erosive esophagitis.
Read the full report at AstraZeneca-US. 
These findings support the results of previous head-to-head trials demonstrating the efficacy of NEXIUM® as compared to other proton pump inhibitors (PPIs) in maintaining erosive esophageal healing.
Comment Preview